BMRN stock · EBS stock

BMRN vs EBS

Biomarin Pharmaceutical Inc (BMRN) versus Emergent Biosolutions Inc (EBS) — a side-by-side from cached financials, not a winner call.

Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.

Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.

Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.

Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.

BMRN currently screens at market cap $10.63B and trailing P/E 39.6. EBS currently screens at market cap $416.4M.

Not investment advice. Open the BMRN and EBS stock pages for the full models.

Not investment advice.

Popular Stock Comparisons